Table 1 Clinical trials using injectable growth factor
From: Clinical application of injectable growth factor for bone regeneration: a systematic review
Target disease, year, author | Growth factor | Carrier, product characters | Number of patients | Results | Severe adverse events |
|---|---|---|---|---|---|
Critical limb ischemia, 2007, Marui et al. [10] | rhFGF-2, 200 μg | Gelatin hydrogel, injectable syringe | 7 | Vascular regeneration | No severe adverse events |
Knee osteotomy for osteoarthritis, 2007, Kawaguchi et al. [11] | rhFGF-2; 200, 400, 800 μg | Gelatin hydrogel, injectable syringe | 57 | Dose-dependent early bone healing | Recovered without problem |
rhFGF-2; 0.03%, 0.1%, 0.3% | Hydroxypropylcellulose, injectable syringe | 59 | Periodontal regeneration | Recovered without problem | |
Tibial fracture, 2010, Kawaguchi et al. [14] | rhFGF-2; 800, 2400 μg | Gelatin hydrogel, injectable syringe | 47 | Early bone healing | Recovered without problem |
Glucocorticoid-resistant sudden sensorineural hearing loss, 2010, Nakagawa et al. [15] | rhIGF-1, 10 mg | Gelatin hydrogel, injectable | 25 | Hearing improvement | Recovered without problem |
Sudden deafness refractory to systemic corticosteroid treatment, 2014, Nakagawa et al. [16] | rhIGF-1, 300 μg | Gelatin hydrogel, injectable | 62 | Hearing improvement | Recovered without problem |
Osteonecrosis of the femoral head, 2011, Kuroda et al. [17] | rhFGF-2, 800 μg | Gelatin hydrogel, sheet, injectable | 10 | Nine of ten patients revealed bone regeneration | Recovered without problem |
Osteonecrosis of the femoral head, Completed March 2019, Kuroda et al. | rhFGF-2, 800 μg | Gelatin hydrogel, injectable syringe | 64 | Under evaluation | Under evaluation |